Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,970,129
  • Shares Outstanding, K 94,506
  • Annual Sales, $ 1,243 M
  • Annual Income, $ -535,980 K
  • 60-Month Beta 0.94
  • Price/Sales 9.79
  • Price/Cash Flow N/A
  • Price/Book 14.02
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 60.72% ( -2.95%)
  • Historical Volatility 27.68%
  • IV Percentile 56%
  • IV Rank 11.68%
  • IV High 247.47% on 10/20/23
  • IV Low 36.02% on 12/01/23
  • Put/Call Vol Ratio 0.43
  • Today's Volume 1,914
  • Volume Avg (30-Day) 1,327
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 75,727
  • Open Int (30-Day) 74,969

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 8
  • High Estimate 0.13
  • Low Estimate -0.62
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +92.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.37 +14.45%
on 04/19/24
131.80 -0.68%
on 04/29/24
+2.50 (+1.95%)
since 04/01/24
3-Month
114.37 +14.45%
on 04/19/24
143.00 -8.46%
on 02/16/24
+8.07 (+6.57%)
since 02/01/24
52-Week
55.25 +136.92%
on 10/31/23
159.89 -18.13%
on 05/15/23
+5.79 (+4.63%)
since 05/01/23

Most Recent Stories

More News
Sarepta Therapeutics: Q1 Earnings Snapshot

Sarepta Therapeutics: Q1 Earnings Snapshot

SRPT : 130.90 (+3.35%)
1 Top Growth Stock to Buy and Hold for 10 Years

This company's lineup might look very different in a decade, but the end result will be the same for investors.

SRPT : 130.90 (+3.35%)
2 Biotech Stocks to Buy Hand Over Fist in April

These drugmakers have made important moves over the past year.

AMGN : 277.37 (+1.25%)
SRPT : 130.90 (+3.35%)
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

The threat is still emerging, but it could be significant.

SRPT : 130.90 (+3.35%)
RGNX : 16.20 (+5.54%)
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

SRPT : 130.90 (+3.35%)
ENPH : 105.16 (-3.31%)
GOOG : 165.57 (+0.56%)
GOOGL : 163.86 (+0.66%)
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

The upcoming regulatory decision on its latest drug could be big.

SRPT : 130.90 (+3.35%)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.

SRPT : 130.90 (+3.35%)
Sarepta Therapeutics: Q4 Earnings Snapshot

Sarepta Therapeutics: Q4 Earnings Snapshot

SRPT : 130.90 (+3.35%)
Is It Too Late to Buy Sarepta Therapeutics Stock?

The company's hyperfocus on its core area could continue to be highly lucrative.

SRPT : 130.90 (+3.35%)
Why Sarepta Therapeutics Stock Is Soaring Today

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

JPM : 191.86 (+0.06%)
SRPT : 130.90 (+3.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 137.28
2nd Resistance Point 134.45
1st Resistance Point 132.67
Last Price 130.90
1st Support Level 128.06
2nd Support Level 125.23
3rd Support Level 123.45

See More

52-Week High 159.89
Last Price 130.90
Fibonacci 61.8% 119.92
Fibonacci 50% 107.57
Fibonacci 38.2% 95.22
52-Week Low 55.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar